Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2003
11/13/2003US20030212091 Aryl ether substituted imidazoquinolines
11/13/2003US20030212088 Methods and compositions for treating, preventing or delaying onset of a neoplasm
11/13/2003US20030212087 Plant extracts; antitumor, anticancer agents; topoisomerase inhibitor
11/13/2003US20030212082 Controlling neovascularization; angiogenesis inhibitors; therapy for strokes, cardiovascular disorders; antitumor agents; antidiabetic agents; antiarthritic agents; psoriasis
11/13/2003US20030212073 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
11/13/2003US20030212067 Bone disorders; rheumatic diseases; wound healing agents
11/13/2003US20030212061 Aza-thioxanthenones with antitumor activity
11/13/2003US20030212055 Cinnoline compounds
11/13/2003US20030212048 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
11/13/2003US20030212038 Anticancer agents; side effect reduction; synergistic mixture of antifolic acid and reducing methylmalonic acid concentration
11/13/2003US20030212032 Oligonucleotide N3'→P5' thiophosphoramidates: their synthesis and use
11/13/2003US20030212026 Induce immunology response
11/13/2003US20030212020 Antisense modulation of macrophage migration inhibitory factor expression
11/13/2003US20030212008 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
11/13/2003US20030211986 Protein a compositions and methods of use
11/13/2003US20030211613 Methods of altering calcium transport
11/13/2003US20030211607 Antisense modulation of survivin expression
11/13/2003US20030211583 Egs molecules that specifically downregulae bcl-xl experession
11/13/2003US20030211553 Selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
11/13/2003US20030211515 Comprises nucleotide sequences coding matrix protein for diagnosing and treating cancer
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003US20030211493 Comprises membrane protein for diagnosis, prevention and treatment of infections, cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory and metabolic disorders
11/13/2003US20030211477 Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
11/13/2003US20030211468 Comprises monoclonal antibody which deactivates kaposi's sarcoma associated herpesvirus interleukin-6 (KSRV VIL-6) for treating, diagnosing and prognosing oncogenic viral infections; antiarthritic agents; antitumor agents
11/13/2003US20030211180 Viricides, anticancer agents; side effect reduction
11/13/2003US20030211171 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
11/13/2003US20030211165 Anticancer agents; mixture of hydrophilic, crosslinked polymer and drugs
11/13/2003US20030211132 Method for reducing radioactivity in the human body
11/13/2003US20030211112 EGFR ligands and methods of use
11/13/2003US20030211100 Gene therapy; nucleic acid coding immunoglobulins; anticancer agents
11/13/2003US20030211097 Epidermal growth factor; antitumor, anticancer agents
11/13/2003US20030211079 Immobilization with polyoxyethylene glycol; adjust circulation half-life
11/13/2003US20030211077 Stimulanting hematopoiesis
11/13/2003US20030211075 Mixture of sensitizer and tissue factor
11/13/2003US20030211040 Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
11/13/2003US20030211038 Calibration sensitive toxicity to radioimmunotherapy; administering radioactive antibodies; measurement bone marrow
11/13/2003CA2703698A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003CA2487693A1 Method for producing preparations rich in tocotrienol
11/13/2003CA2485098A1 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003CA2485065A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003CA2484976A1 Method of inhibiting angiogenesis
11/13/2003CA2484963A1 7-hydroxy-16a-fluoro-5-androsten-17-ones and 7-hydroxy-16a-fluoro-5-androstan-17-ones and derivatives thereof
11/13/2003CA2484874A1 Monocompartment osmotic controlled drug delivery system
11/13/2003CA2484597A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003CA2484582A1 Bombesin antagonists
11/13/2003CA2484551A1 Smart pro-drugs of serine protease inhibitors
11/13/2003CA2484538A1 Vectors with modified protease-dependent tropism
11/13/2003CA2484425A1 Fusions of cytokines and tumor targeting proteins
11/13/2003CA2484420A1 Antibodies specific for human cd22 and their therapeutic and diagnostic uses
11/13/2003CA2484312A1 Catechin multimers as therapeutic drug delivery agents
11/13/2003CA2484258A1 Soya cell strains with high isoflavone content
11/13/2003CA2484209A1 Protein kinase modulators and methods of use
11/13/2003CA2484189A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003CA2484173A1 4-azasteroid derivatives as androgen receptor modulators
11/13/2003CA2484065A1 Inhibitors of histone deacetylase
11/13/2003CA2483996A1 Promoters exhibiting endothelial cell specificity and methods of using same
11/13/2003CA2483912A1 Alcam and alcam modulators
11/13/2003CA2483909A1 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003CA2483846A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003CA2483843A1 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
11/13/2003CA2483806A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003CA2483787A1 Melanocortin receptor ligands
11/13/2003CA2483785A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
11/13/2003CA2483552A1 Calicheamicin derivative-carrier conjugates
11/13/2003CA2483532A1 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
11/13/2003CA2483529A1 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles
11/13/2003CA2483084A1 Tyrosine kinase inhibitors
11/13/2003CA2482967A1 Binary or polynary targeting and uses thereof
11/13/2003CA2482784A1 Composition for treating cancer containing n,n-dimethylphytosphingosine
11/13/2003CA2480008A1 Use of il-13 receptor subunit alpha 2 as an anti-cancer vaccine
11/13/2003CA2462879A1 Immunoconjugates for the treatment of tumours
11/13/2003CA2462645A1 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
11/12/2003EP1361268A1 Pax-5-deficient pro-B cells, methods of producing them and the use of such cells in human therapy
11/12/2003EP1361225A1 Compounds substituted with bicyclic amino groups
11/12/2003EP1361224A1 Heterocyclic hydrazones for use as anti-cancer agents
11/12/2003EP1361222A1 Sidechain-bearing taxanes
11/12/2003EP1360964A1 Use of galanin-like peptide
11/12/2003EP1360963A2 Ganglioside-KLH conjugate vaccines with QS-21
11/12/2003EP1360959A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy
11/12/2003EP1360500A2 Methods for selective targeting
11/12/2003EP1360486A2 Screening method for identifying compounds that selectively induce interferon alpha
11/12/2003EP1360319A2 Diagnosis of diseases associated with metabolism
11/12/2003EP1360307A2 Chimeric polypeptides of serum albumin and uses related thereto
11/12/2003EP1360304A2 Enzymes
11/12/2003EP1360299A2 The genome of a bifidobacterium
11/12/2003EP1360295A2 Molecules for desease detection and treatment
11/12/2003EP1360293A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
11/12/2003EP1360291A2 Human polynucleotides and polypeptides encoded thereby
11/12/2003EP1360208A1 Induvidualized anti-cancer antibodies
11/12/2003EP1360205A1 Angiogenesis-inhibitory tripeptides, compositions and their methods of use
11/12/2003EP1360203A1 Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
11/12/2003EP1360189A1 Formulation of boronic acid compounds
11/12/2003EP1360186A2 Carboline derivatives
11/12/2003EP1360185A2 Carboline derivatives
11/12/2003EP1360180A1 Phenothiazine kinesin inhibitors
11/12/2003EP1360178A2 Novel heterocyclic analogs of diphenylethylene compounds
11/12/2003EP1360175A1 1g(a)-amino-n-hydroxy-acetamide derivatives
11/12/2003EP1360173A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/12/2003EP1359979A2 Anti cancer combination of substituted pyrroles and paclitaxel
11/12/2003EP1359943A2 Biotin-derivates and their conjugates with chelating agents
1 ... 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 ... 2211